REZOLUTE INC

RZLTNASDAQ

🏆 #2587 by market capEarnings Sep 15 · PostUS Equity

$4.62▼ $0.06 (−1.28%)

🌅 Pre-market$4.69▲ 1.52%Regular close · extended-hours price shown

1h—

24h▼ 1.3%

7d▼ 1.3%

14d▼ 1.7%

30d▼ 2.5%

1y▼ 25.5%

🏦Market Cap

$445M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $4.56 – $4.69
52-Week Range: $1.07 – $11.46
Volume: $3.31B
Avg Volume: $4.01B
Shares Outstanding: 96.3M
Next Earnings: Sep 28, 2026

Fundamentals Snapshot

Annual Revenue: $86M
Last Q Revenue: $21M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.81
Dividend Yield: —

Why Investors Own RZLT

✓High-growth profile — revenue up +58.3% YoY with expanding US Equity exposure.
✓Healthy economics — 36% gross margin and 19% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$86M▲ +50.9% YoY

Gross Margin (TTM)

36.3%▲ +3.1% YoY

Operating Income (TTM)

$28M▲ +50.9% YoY

Free Cash Flow (TTM)

$16M▲ +50.9% YoY

About REZOLUTE INC

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

🦦